Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Rev. bras. hematol. hemoter ; 32(4): 303-307, 2010. graf, tab
Article in English | LILACS | ID: lil-561370

ABSTRACT

The outcome of Hodgkin's lymphoma (HL) has markedly improved over the last few decades, placing HL among the human cancers with highest cure rates. However, data about treatment outcomes in developing countries are scarce. From 1996 to 2005, 370 consecutive patients with HL treated in three public institutions in Rio de Janeiro were identified. A total of 216 patients who presented with advanced stage (IIB-IV) HL were selected for the present analysis. Patients with advanced disease were treated with ABVD, complemented or not by radiation therapy. The median follow-up time of survivors was 6.3 years (1-11.8). Fifteen patients died during first-line treatment. The complete remission rate was 80 percent. The 5-year progression-free survival (PFS) and the 5-year overall survival (OS) probabilities were 69 percent and 83 percent, respectively. The 5-year PFS in low-risk and high-risk patients were 81 percent and 62 percent (p=0.003), respectively. The 5-year OS in low-risk and high-risk International Prognostic Score patients were 89 percent and 78 percent (p=0.02), respectively. The present study provides a representative estimate of current treatment results for advanced HL in public institutions in an urban area in Brazil. It is clear that full treatment can be given to most patients, although those with very low socio-economic status might require special attention and support. Since Brazil is a large country, with substantial interregional heterogeneity, a nationwide registry of HL patients is currently being implemented.


Os resultados do tratamento do linfoma de Hodgkin (LH) melhoraram substancialmente ao longo das últimas décadas e tornaram o LH uma das neoplasias humanas com maior chance de cura. Entretanto, os dados sobre tratamento em países em desenvolvimento são escassos. Entre 1996 e 2005, 370 pacientes consecutivos com LH tratados em três instituições públicas no Rio de Janeiro foram identificados. Destes, 216 em estádio avançado (IIB-IV) foram selecionados para esta análise. Os pacientes foram tratados com o protocolo ABVD (doxorrubicina, bleomicina, vinblastina e dacarbazina). A mediana do tempo de seguimento dos sobreviventes foi de 6,3 anos (1-11,8). Quinze pacientes morreram durante o tratamento de primeira linha. A probabilidade de sobrevida livre de progressão (SLP) em cinco anos e a probabilidade de sobrevida global (SG) em cinco anos foram de 69 por cento e 83 por cento, respectivamente. A SLP nos grupos de baixo risco e de alto risco, de acordo com o "International Prognostic Score", foi de 81 por cento e 62 por cento (p=0,003), respectivamente. A SG em cinco anos nos grupos de baixo risco e de alto risco foi de 89 por cento e 78 por cento (p=0,02), respectivamente. O presente estudo apresenta uma estimativa representativa dos resultados atuais do tratamento do LH avançado em instituições públicas no Brasil. Fica claro que o tratamento completo pode ser oferecido à grande maioria dos pacientes, embora aqueles com baixo status socioeconômico possam exigir atenção especial. Em vista das dimensões continentais do Brasil, com substancial heterogeneidade interregional, um registro nacional de pacientes com LH está sendo implementado.


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Middle Aged , Aged, 80 and over , Drug Therapy , Hodgkin Disease , Lymphoma
2.
Leuk Lymphoma ; 50(11): 1830-6, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19883310

ABSTRACT

The human germinal center-associated lymphoma (HGAL) gene has prognostic value in diffuse large B-cell lymphoma, and expression of its cognate protein is germinal center-specific. A previous study had suggested that HGAL protein expression might also be related to the outcome in patients with Hodgkin lymphoma (HL). The aim of this study was to confirm the prognostic impact of HGAL protein expression in an independent, well-characterized cohort of 232 patients with classic HL treated uniformly with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). Tissue microarray analysis showed HGAL staining in 188 specimens (81%). Failure-free survival (FFS) was superior in patients with early-stage disease, low-risk IPS, and HGAL-positive patients. The estimated 5-year FFS for HGAL-positive and HGAL-negative patients was 82% and 67%, respectively (p = 0.03). In the multivariate analysis, advanced stage and absence of HGAL staining were independent predictors of a worse FFS. This study confirms and validates recent findings of a correlation between HGAL expression and outcome in classical HL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Hodgkin Disease/metabolism , Neoplasm Proteins/biosynthesis , Adolescent , Adult , Aged , Aged, 80 and over , Bleomycin/administration & dosage , Brazil , Cohort Studies , Dacarbazine/administration & dosage , Doxorubicin/administration & dosage , Female , Germinal Center/metabolism , Germinal Center/pathology , Hodgkin Disease/pathology , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins , Male , Microfilament Proteins , Middle Aged , Predictive Value of Tests , Prognosis , Survival Analysis , Tissue Array Analysis , Treatment Outcome , Vinblastine/administration & dosage , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...